Editorial: Stem cell funding is venture capital
By San Francisco Examiner,
San Francisco Examiner
| 08. 30. 2005
Last year's predictions of the benefits California would derive from approving Proposition 71 and funding stem cell research were overly optimistic, a recent study proclaimed.
The report, funded by universities and a biomedical trade association, concluded that while the state would benefit from new jobs, tax revenues and improvements to public health, requiring companies to pay for their use of research funding would stifle the participation of businesses.
In a sense, those using the report to oppose measures now under consideration in the state Legislature to codify how California will benefit from stem cell research are saying they want to consider billions of dollars in taxpayers' money not as a loan for investment purposes _ venture capital _ but instead as an outright gift.
Including interest, state taxpayers will likely end up paying $6 billion or more to repay the $3 billion in bonds.
The stem cell institute is scheduled to disburse its first grants soon, so let's be clear: Prop. 71's $3 billion in public money was not meant to be a gift. It was meant to be an...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...